Sister Chromatid Exchange Rate and Alkaline Comet Assay Scores in Patients with Ovarian Cancer

Baltacı, Volkan; Kayıkçıoğlu, Fulya; Alpas, İdil; Zeyneloğlu, Hulusi Bülent; Haberal, Alı

doi:10.1006/gyno.2001.6450

Cited by 25 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the peripheral lymphocytes from patients with carcinoma of the cervix uteri were found to have a mean of 7.8 SCEs per metaphase, which was slightly higher than that of the control group [19]. An increased level of SCEs has also been observed in the lymphocytes from patients with ovarian cancer, where there was a mean value of 18 SCEs per cell, which was significantly higher than the lymphocytes from healthy volunteers (6.9 per cell) [20]. Likewise, lymphocytes from patients with hereditary breast cancer had on average 11 SCEs per cell, which was significantly higher than those of the control group (7.7 SCEs per cell) [21].…”

Section: Discussionmentioning

confidence: 99%

Cytogenetic Finding of Breast Cancer Cases and in Their First-Degree Relatives

et al. 2013

View full text Add to dashboard Cite

PurposeThe aim of this study was to evaluate and compare the rate of sister chromatid exchange (SCE), the occurrence of micronuclei, and the lymphocyte proliferation rate index (PRI) in patients with breast cancer, their first-degree relatives, and healthy volunteers.MethodsWe analyzed the frequency of SCE and micronuclei, and the PRI in the peripheral blood lymphocytes of 30 women with breast cancer, 22 of their female family members, and 20 age-matched healthy female volunteers.ResultsSCE occurred significantly more often in the lymphocytes of breast cancer patients (10.84±0.4 per metaphase), compared with their first-degree relatives (7.45±0.54) and controls (5.94±0.2) (p<0.001 for both). The mean SCE frequency was not statistically different between first-degree relatives and controls (p=0.071). Similarly, micronuclei occurred at a significantly higher rate in breast cancer patients (9.6±0.72), and in their first-degree relatives (7±0.64), compared to controls (3.85±0.4) (p<0.001 and p=0.001, respectively). There was also a significant difference between the occurrence of micronuclei in patients compared to their family members (p=0.021). The PRI was significantly lower in patients (1.61±0.1), compared with both their first-degree relatives (1.75±0.1), and controls (1.74±0.1) (p=0.001 and p=0.002, respectively).ConclusionIncreased SCE and the occurrence of micronuclei, as well as a reduced PRI are associated with breast cancer. Furthermore, increased SCE and the frequency of micronuclei in a first-degree relative suggest that they exhibit greater genetic instability than women of the same age.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytogenetic Finding of Breast Cancer Cases and in Their First-Degree Relatives

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In the last years the alkaline comet assay has gained increased application in clinical medicine. The majority of the reports were concerned with either biomonitoring of increased level of basal DNA damage in cancer patients [18][19][20][21][22] and their female relatives [23] or excess DNA damage caused by treatment with antineoplastic drugs or radiation [24][25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells

et al. 2006

View full text Add to dashboard Cite

The sensitivity of the alkaline comet assay for the evaluation of baseline and treatment-induced DNA damage in white blood cells of breast cancer patients receiving adjuvant chemotherapy according to three conventional anthracycline- and cyclophosphamide-containing protocols was investigated. Additionally, baseline DNA damage in cancer patients was compared with the levels of DNA damage recorded in healthy women. Altogether 30 patients with diagnosed breast cancer and 30 female blood donors with no known familial history of breast cancer participated in the study. Alkaline comet assay was performed according to standard protocol and DNA migration in peripheral blood leukocytes was measured by a computer-based image analysis system. For each subject the frequency of "damaged" cells, i.e., long-tailed nuclei (LTN) with tail length exceeding 95th percentile for the considered parameter among controls, is also reported. Breast cancer patients had significantly increased background levels of DNA damage in their peripheral blood leukocytes as compared to healthy women. Prior to the chemotherapy, a majority of patients showed a statistically significant increase in the number of LTN compared to healthy blood donors. Marked interindividual variations in baseline DNA damage among patients were recorded, some of them related to the disease stage and status. The present study confirmed the alkaline comet assay as a sensitive technique able to detect significantly elevated DNA migration in blood cells of patients already one hour after completion of the first cycle of chemotherapy. Administration of antineoplastic drugs in three chemotherapy protocols studied induced a similar increase of primary DNA damage in nontarget cells. The evaluation of the LTN frequencies indicates the best response to the protocol containing cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Our results point to the significance of simultaneous evaluation of DNA migration and frequency of LTN in the same subject and approved the use of alkaline comet assay as a suitable method for the routine detection of critical DNA lesions produced after administration of antineoplastic drugs in the clinical settings.

show abstract

“…In addition, the highest DNA damage in Barrett's mucosa was associated with an increased risk of developing adenocarcinoma [27]. A study on women with ovarian malignancies showed a signifi cant diff erence in the number of damaged cells between patients and control group [28]. Palyvoda et al investigated squamous cell carcinoma of the head and neck and found that the level of background DNA damage before irradiation, as measured by comet assay, was signifi cantly higher in the head and neck cancer patient group than in the group of healthy subjects, while the parameters of repair were widely scattered in both groups.…”

Section: Cancer and Comet Assaymentioning

confidence: 98%

Application of the comet assay method in clinical studies

Fikrová

Štětina

Hronek

et al. 2011

Wien Klin Wochenschr

View full text Add to dashboard Cite

The comet assay or single-cell gel electrophoresis (SCGE) assay is now widely accepted as a standard method for assessing DNA damage in individual cells. It finds use in a broad variety of applications including human biomonitoring, genotoxicology, ecological monitoring and as a tool for investigation of DNA damage and repair in different cell types in response to a range of DNA-damaging agents. The comet assay should be eminently suitable for use in clinical practice since it is a relatively simple and inexpensive technique which requires only a few cells, and results can be obtained within a matter of hours. This method can be used in the study of cancer as well as in lifestyle and dietary studies. In cancer it is useful for measuring DNA damage before, throughout and after therapy (either radiotherapy or chemotherapy). Another use of this method is in lifestyle study, such as investigation of the effect on DNA of common human activities (e.g. smoking, or working with a potentially genotoxic agent). The final use of comet assay in this paper is dietary study. In this type of study we observe the effects of consumption of specific foods or supplements which may be protective for DNA against damage.

show abstract

Sister Chromatid Exchange Rate and Alkaline Comet Assay Scores in Patients with Ovarian Cancer

Cited by 25 publications

References 9 publications

Cytogenetic Finding of Breast Cancer Cases and in Their First-Degree Relatives

Cytogenetic Finding of Breast Cancer Cases and in Their First-Degree Relatives

Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells

Application of the comet assay method in clinical studies

Contact Info

Product

Resources

About